|
[1]
|
Moog F,Bangerter M,Diederichs CG,et al.Extran-odal malignant lymphoma:detection with 18F-FDG PET versus CT[J].Radiology,1998,206(2):475-481. |
|
[2]
|
Thill R,Neuerburg J,Fabry U,et al.Comparison of findings with 18-F-FDG PET and CT in pretherapeutic staging of malignant lymphoma[J].Nukearmedizin,1997,36(7):234-239. |
|
[3]
|
Hoh CK,Glaspy J,Rosen P,et al.Whole-body 18F-FDG PET imaging for staging of Hodgkin's disease and lymphoma[J].J Nucl Med,1997,38(3):343-348. |
|
[4]
|
Moog F,Kotzerke J,Reske SN.18F-FDG PET call replace bone scintigraphy in primary stagiag of malig-nant lymphoma[J].J Nucl Med,1999,40(9):1407-1413. |
|
[5]
|
Carr R,Barrington SF,Madan B.et al.Detection of lymphoma in bone marrow by whole-body positron e-mission tomoraphy[J].Blood,1998,91(9):3340-3346. |
|
[6]
|
Moog F,Bangerter M,Kotzerke J,et al.18-F-fluo-rodeoxyglucose-positron emission tomograpby as a new approach to detect lymphomatous bone marrow[J].J Clin Oncol,1998,16(2):603-609. |
|
[7]
|
Lapela M,Leskiinen S,Minn HR,et al.Hlcreased glucose metabolism in mlffeated non-Hodgkin's lym-phoma:a study with positon emission tomography and fluorine-18-auorodeoxyglucose[J].Blood,1995,86(9):3522-3527. |
|
[8]
|
Jerusalem G,Begnin Y,Fassotte M F,et al.Persis-tent tumor 18F-FDG uptake after a few cycles of poly-chemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma[J].Haematologica,2000,85(6):613-618. |
|
[9]
|
Romer W,Hallauske AR,Ziegler S,et al.Positron e-mission tomography in non-Hodgkin's lymphoma:as-sessment of chemodlerapy with fluorodeoxyglucose[J].Blood,1998,91(12):4464-4471. |
|
[10]
|
Calleuos GP.Residual mass in lymphoma may not be residual disease[J].J Clin Oncol,1988,6(6):931. |
|
[11]
|
De Wit M,Bumann D,Beyer W,et al.Whole-body positron emission tomography (PET) for diagnosis of residual mass in patient with lymphoma[J].Ann On-col,1997,8(suppl 1):57-60. |
|
[12]
|
Cremerius U,Fabry U,Neuerbmg J,et al.Positron emission tomography widl 18F-FDG to detect residual disease after dlerapy for malignant lymphoma[J].Nu-cl Med Commun,1998,19(11):1055-1063. |
|
[13]
|
Maisey NR,Hill M E,Webb A,et al.Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the predic-tion of relapse in lymphoma residual masses?[J].Eur J Cancer,2000,36(2):200-206. |
|
[14]
|
Shin M S,HO KJ.Diffuse thymic hyperplasia follow-ing chemotherapy for nodular sclerosing Hodgkin's disease:An immunologic rebound phenomenon?[J].Cancer,1983,51(1):30-33. |
|
[15]
|
Wenblatt M E,Zanzi I,Belakhlef A,et al.False-posi-tive 18F-FDG PET imaging of the thymus of a child with Hodgkin's disease[J].JNucl Med,1997,38(6):888-890. |
|
[16]
|
Jerusalem G,Beguin Y,Fassotte M F,et al.Whole-body positron emission tomography using 18F-fluo-rodeoxyglucse for posttreatrment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computer tomography scan imaging[J].Blood,1999,94(2):429-433. |
DownLoad: